Literature DB >> 19482027

Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice.

Xinhua Chen1, Johannes Fruehauf, Jeffrey D Goldsmith, Hua Xu, Kianoosh K Katchar, Hon-Wai Koon, Dezheng Zhao, Efi G Kokkotou, Charalabos Pothoulakis, Ciarán P Kelly.   

Abstract

BACKGROUND & AIMS: Saccharomyces boulardii (Sb) is a probiotic yeast with anti-inflammatory and anti-microbial activities and has been used for decades in the prevention and treatment of a variety of human gastrointestinal disorders. We reported previously that Sb modulates host inflammatory responses through down-regulation of extracellular signal-regulated kinase (Erk)1/2 activities both in vitro and in vivo. The aim of this study was to identify upstream mediators responsible for extracellular signal-regulated kinase (Erk)1/2 inactivation and to examine the effects of Sb on tumor development in Apc(Min) mice.
METHODS: Signaling studies of colon cancer cells were done by western blot. Cell proliferation was measured by MTS and BrdU assay. Apoptosis was examined by flow cytometry, tunel assay and caspase assay. Apc(Min) mice were orally given Sb for 9 weeks before sacrifice for tumor analysis.
RESULTS: We found that the epidermal growth factor receptor (EGFR) was deactivated upon exposure to Sb, leading to inactivation of both the EGFR-Erk and EGFR-Akt pathways. In human colonic cancer cells, Sb prevented EGF-induced proliferation, reduced cell colony formation, and promoted apoptosis. HER-2, HER-3, and insulin-like growth factor-1 receptor were also found to be inactivated by Sb. Oral intake of Sb reduced intestinal tumor growth and dysplasia in C57BL/6J Min/+ (Apc(Min)) mice.
CONCLUSIONS: Thus, in addition to its anti-inflammatory effects, Sb inhibits EGFR and other receptor tyrosine kinase signaling and thereby may also serve a novel therapeutic or prophylactic role in intestinal neoplasia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482027      PMCID: PMC2777664          DOI: 10.1053/j.gastro.2009.05.050

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

Review 1.  The role of probiotic bacteria in cancer prevention.

Authors:  K Hirayama; J Rafter
Journal:  Microbes Infect       Date:  2000-05       Impact factor: 2.700

2.  Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells.

Authors:  D Czerucka; S Dahan; B Mograbi; B Rossi; P Rampal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  The place of probiotics in human intestinal infections.

Authors:  A Sullivan; C E Nord
Journal:  Int J Antimicrob Agents       Date:  2002-11       Impact factor: 5.283

4.  Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

Authors:  A Qamar; S Aboudola; M Warny; P Michetti; C Pothoulakis; J T LaMont; C P Kelly
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis.

Authors:  Reade B Roberts; Lu Min; M Kay Washington; Sandra J Olsen; Stephen H Settle; Robert J Coffey; David W Threadgill
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

Review 6.  Regulation of growth factor receptors by gangliosides.

Authors:  Erik A Miljan; Eric G Bremer
Journal:  Sci STKE       Date:  2002-11-26

7.  Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Authors:  M Guslandi; G Mezzi; M Sorghi; P A Testoni
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

8.  Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells.

Authors:  Stephanie Dahan; Guillaume Dalmasso; Veronique Imbert; Jean-Francois Peyron; Patrick Rampal; Dorota Czerucka
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 9.  Insulin and insulin-like growth factor signalling in neoplasia.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

Review 10.  Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.

Authors:  S M Huang; P M Harari
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

View more
  26 in total

1.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

Review 2.  Recent advances in small bowel diseases: Part I.

Authors:  Alan B R Thomson; Angeli Chopra; Michael Tom Clandinin; Hugh Freeman
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

3.  Inhibitory effect of Lactobacillus acidophilus on Helicobacter hepaticus in vitro.

Authors:  Manhua Zhang; Haiyang Zhang; Yan Li; Wenqian Qi; Xu Wang; Jiangbin Wang
Journal:  World J Microbiol Biotechnol       Date:  2013-01-05       Impact factor: 3.312

4.  Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.

Authors:  Hon Wai Koon; David Q Shih; Tressia C Hing; Jun Hwan Yoo; Samantha Ho; Xinhua Chen; Ciarán P Kelly; Stephan R Targan; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

5.  Anticancer Properties of Probiotic Saccharomyces boulardii Supernatant on Human Breast Cancer Cells.

Authors:  Babak Pakbin; Shaghayegh Pishkhan Dibazar; Samaneh Allahyari; Maryam Javadi; Zahra Amani; Alireza Farasat; Sina Darzi
Journal:  Probiotics Antimicrob Proteins       Date:  2022-01-30       Impact factor: 4.609

6.  Association of Vitamin B12, Lactate Dehydrogenase, and Regulation of NF-κB in the Mitigation of Sodium Arsenite-Induced ROS Generation in Uterine Tissue by Commercially Available Probiotics.

Authors:  Sandip Chattopadhyay; Shamima Khatun; Moulima Maity; Suryashis Jana; Hasina Perveen; Moumita Dash; Arindam Dey; Lipi Rani Jana; Pikash Pratim Maity
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

7.  Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells.

Authors:  Galliano Zanello; Mustapha Berri; Joëlle Dupont; Pierre-Yves Sizaret; Romain D'Inca; Henri Salmon; François Meurens
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

8.  Probiotics, nuclear receptor signaling, and anti-inflammatory pathways.

Authors:  Sonia S Yoon; Jun Sun
Journal:  Gastroenterol Res Pract       Date:  2011-07-26       Impact factor: 2.260

Review 9.  Potential role of probiotics on colorectal cancer prevention.

Authors:  Mario Uccello; Giulia Malaguarnera; Francesco Basile; Velia D'agata; Michele Malaguarnera; Gaetano Bertino; Marco Vacante; Filippo Drago; Antonio Biondi
Journal:  BMC Surg       Date:  2012-11-15       Impact factor: 2.102

10.  Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation.

Authors:  Xinhua Chen; Guoxun Yang; Joo-Hye Song; Hua Xu; Dan Li; Jeffrey Goldsmith; Huiyan Zeng; Patricia A Parsons-Wingerter; Hans-Christian Reinecker; Ciaran P Kelly
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.